tiprankstipranks
Trending News
More News >
Grifols SA (GRFS)
NASDAQ:GRFS

Grifols SA (GRFS) Price & Analysis

Compare
433 Followers

GRFS Stock Chart & Stats


Financials

Ownership Overview

8.52%41.15%49.34%
Insiders
41.15% Other Institutional Investors
49.34% Public Companies and Individual Investors

GRFS FAQ

What was Grifols SA’s price range in the past 12 months?
Grifols SA lowest stock price was $5.79 and its highest was $9.96 in the past 12 months.
    What is Grifols SA’s market cap?
    Grifols SA’s market cap is $7.41B.
      When is Grifols SA’s upcoming earnings report date?
      Grifols SA’s upcoming earnings report date is Jul 24, 2025 which is in 42 days.
        How were Grifols SA’s earnings last quarter?
        Grifols SA released its earnings results on May 12, 2025. The company reported $0.092 earnings per share for the quarter, missing the consensus estimate of $0.149 by -$0.057.
          Is Grifols SA overvalued?
          According to Wall Street analysts Grifols SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Grifols SA pay dividends?
            Grifols SA pays a Annually dividend of $0.345 which represents an annual dividend yield of N/A. See more information on Grifols SA dividends here
              What is Grifols SA’s EPS estimate?
              Grifols SA’s EPS estimate is 0.22.
                How many shares outstanding does Grifols SA have?
                Grifols SA has 261,425,100 shares outstanding.
                  What happened to Grifols SA’s price movement after its last earnings report?
                  Grifols SA reported an EPS of $0.092 in its last earnings report, missing expectations of $0.149. Following the earnings report the stock price went up 8.873%.
                    Which hedge fund is a major shareholder of Grifols SA?
                    Currently, no hedge funds are holding shares in GRFS

                    Company Description

                    Grifols SA

                    Grifols SA is a global healthcare company based in Spain, specializing in the production of plasma-derived medicines and transfusion medicine. The company operates through four main divisions: Bioscience, Diagnostic, Hospital, and Bio Supplies. Grifols is a leader in the production of plasma-derived products, which are used to treat a variety of chronic, rare, and often life-threatening conditions. Their product portfolio includes treatments for bleeding disorders, immune deficiencies, and neurological disorders.

                    GRFS Company Deck

                    GRFS Earnings Call

                    Q1 2025
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    Grifols reported strong Q1 2025 performance with record revenue and growth, particularly in the immunoglobulin franchise. Despite challenges like negative free cash flow due to a strategic payment and temporary albumin issues, the company showed robust adjusted EBITDA and continued deleveraging efforts. The results are ahead of plan even amidst macroeconomic uncertainties and IRA impacts.Read More>
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Bristol-Myers Squibb
                    Gilead Sciences
                    GlaxoSmithKline
                    Pfizer
                    Sanofi
                    Popular Stocks
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis